Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (16065) (UNITY205)
Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (16065) (UNITY205)
Trial Category:
Lymphoma
Phase
II
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
Southeast Nebraska Cancer Center, Lincoln, NE
This study is for patients previously treated for non-hodgkins lymphoma. Patients are "randomized" on this study. This means a computer tells the study team which treatment you will receive. Neither the patient or the physician can choose the treatment assignment. The purpose of Randomized trials is to equally study both treatment options using the same criteria in order to identify if one treatment may be superior to another treatment.
